



1

Disclaimer

This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country.

2

2

Agenda

Highlights	Guillaume Daniellot
Business & regional review	Peter Hackel
Recent achievements & strategy in action	Guillaume Daniellot
Outlook 2021	Guillaume Daniellot
Q&A and upcoming events	Guillaume Daniellot Peter Hackel

straumanngroup

3




Highlights

Guillaume Daniellot, CEO

straumanngroup

4

Growth further accelerates in the second quarter



5


¹ Organic growth excluding FX and M&A effects ² Barring unforeseen events, assuming the pandemic will not negatively impact the patient flow and excluding FX effects

straumanngroup

5

Very solid two-year average growth rate

Organic revenue growth



6

straumanngroup

6



Business and regional review


Peter Hackel, CFO

straumanngroup

7

Record half-year result

Revenue development by quarter (in CHF million, rounded)




8

straumanngroup

8


Strong revenue growth in the first half of 2021

Revenue development (in CHF million, rounded)



9

EMEA and North America report triple-digit growth



10


* refers to H1

Latin America and Asia Pacific show strong growth

Asia Pacific



Revenue change (organic)



- Increased market share led by China, Japan and Taiwan
- Premium and challenger implant brands drive growth, challengers growing faster
- Orthodontics growing well
- Continued strong growth led by Brazil, Argentina, Chile
- Neodent biggest growth contributor
- Digital solutions going very well, Virtuo Vivo launched

11

* refers to H1

straumanngroup


11

Very dynamic growth in all businesses with clear aligners in the leading position


Implant systems




Digital & restorative



Biomaterials



Orthodontics



12

straumanngroup

12

Core financials at a glance

In CHF million, rounded	H1 2021	% of revenue	Margin change	Change in %	Comments
Revenue	985.5	100.0%		62.9%	
COGS	(233.8)	23.7%		33.4%	
GROSS PROFIT	751.7	76.3%	530bps	74.9%	FX headwind -30bps
Operating expenses	(467.7)	47.5%		41.9%	
EBIT	284.0	28.8%	1220bps	183.4%	FX headwind -30bps
Financial result	(9.6)	1.0%		(20.6%)	
Associates	(1.0)	0.1%		(47.6%)	
Income tax	(45.9)	4.7%		264.6%	
NET PROFIT	227.4	23.1%	1090bps	209.1%	
Basic EPS	14.19			216.3%	

13

straumanngroup

13

Reported financials at a glance

In CHF million, rounded	H1 2021	% of revenue	Margin change	Change in %	Comments
Revenue	985.5	100.0%		62.9%	
COGS	(233.9)	23.7%		27.3%	
GROSS PROFIT	751.6	76.3%	660bps	78.4%	FX headwind -30bps
Operating expenses	(473.0)	48.0%		(4.5%)	
EBIT	278.6	28.3%	4050bps	*	FX headwind -120bps
Financial result	(58.6)	5.9%		163.4%	Thereof earn-out adjustment DrSmile 49.0m
Associates	(1.0)	0.1%		(47.7%)	
Income tax	(44.4)	4.5%		*	In H1 2020 positive tax effect due to impairments
NET PROFIT	174.6	17.7%	3320bps	*	Earn-out adjustment DrSmile -500bps
Basic EPS	10.87			*	

14

* Negative prior year base

straumanngroup

14

Overview: core results reconciliation

(in CHF 1000)	IFRS HY1 2021	PPA amortization	Impairments	Restructuring	Other ¹	CORE HY1 2021	CORE HY1 2020
Revenue	985 487					985 487	605 088
Cost of goods sold	(233 909)	72				(233 837)	(175 267)
Gross profit	751 579	72				751 650	429 822
Other income	2 379					2 379	13 927
Distribution expense	(190 403)	4 189				(186 214)	(140 617)
Administrative expense	(284 947)	1 093				(283 854)	(202 929)
Operating profit	278 608	5 354				283 962	100 203
Finance income	54 306					54 306	41 678
Finance expense	(112 886)				48 951	(63 935)	(53 803)
Gain on consolidation of former associates	0						
Share of result of associates	(1 000)					(1 000)	(1 911)
Profit before income tax	219 027	5 354			48 951	273 333	86 167
Income tax expense	(44 391)	(1 501)				(45 892)	(12 588)
NET PROFIT	174 636	3 853			48 951	227 441	73 579
Attributable to:							
Shareholders of the parent company	172 839	3 758			48 951	225 547	71 229
Non-controlling interests	1 796	96				1 893	2 350
Basic earnings per share (in CHF)	10.87					14.19	4.49
Diluted earnings per share (in CHF)	10.84					14.14	4.48
Operating profit	278 608	5 354				283 962	100 203
Depreciation & amortization	53 964	(5 354)				48 610	40 581
EBITDA	332 571					332 571	140 784

15


¹ Other finance expense refers to an earn-out adjustment for DrSmile

straumanngroup

15

Core gross margin above 76%

In %, rounded




16

straumanngroup

16

Core EBIT margin almost at 29%


In %, rounded



17

Core net profit margin improved to 23%

In CHF million, rounded




18


Historically high free cash flow

In CHF million, rounded

Operating cash flow	In CHF million	Y/Y change
HY1 2020	60.7	
HY1 2021	256.7	+423%



19




Recent achievements & strategy in action

Guillaume Daniellot, CEO

straumanngroup

20

Seizing opportunities in the premium implant market



21

■ Straumann share ■ Market opportunity


Source: STMN Group market model & data 2020

straumanngroup

21

Immediacy driving growth in the premium implant business

- BLX and TLX winning new customers
- BLX is now available in 67 countries
- Immediacy solutions drive growth in the edentulous segment
- TLX on track for full launch in 2nd half of 2021
- ITI World Symposium in September




22

straumanngroup

22

Capturing the huge potential in the value market



23

Source: STMN Group market model & data 2020

straumanngroup

23

Global presence covering all price points



24

straumanngroup

24

Orthodontics business growing very significantly

High-performance material ClearQuartz

- Launched worldwide except for China

Software feature Collaborator

- Enabling doctors to collaborate on cases with their staff, other doctors and treatment planning services

ClearPilot 2.0 software update

- Simple treatment planning for doctors
- Visualization of treatment outcomes to show patients
- Mobile view e.g. for tablet computers



25

straumanngroup

25

Expansion of direct-to-consumer brands for doctor-led clear aligner treatment


DrSmile further expanding in Europe

Established:

- Austria
- France
- Germany
- Spain

Recently rolled out:

- Netherlands
- Poland
- Sweden



Entering the DTC segment in Brazil

- Agreement signed to fully acquire Smilink
- Doctor-led direct-to-consumer clear aligner treatment provider




26

straumanngroup

26

Investing in people to further capture opportunities



>800 new colleagues since December 31

Mainly in:

- **Operations**
supporting Neodent and implant volume growth
- **Orthodontics**
DTC activity (DrSmile development) and production



27

straumanngroup

27

New Chief Information Officer to drive digital transformation



Christian Ullrich

- Chief Information Officer and EMB member as of October 1st
- Impressive track record in leading digital transformation of global companies

28

straumanngroup

28



29

Outlook raised

<p>Market environment</p>	<ul style="list-style-type: none"> ▪ Dental practices operating, healthy patient flows ▪ Group expects softer tailwind in the second half of the year ▪ Pandemic remains unpredictable 	
<p>Our revenue and profitability¹</p>	<ul style="list-style-type: none"> ▪ Strong first-half of 2021 ▪ Group aims to achieve organic revenue growth of above thirty percent ▪ Profitability (core EBIT margin) expected to nearly reach the 2019 level 	

¹ Barring unforeseen events, assuming the pandemic will not negatively impact the patient flow and excluding FX effects

30

straumanngroup

30



Questions & answers

Q & A

straumanngroup

31

Calendar of upcoming events

2021	Event	Location
September 1	Stifel Cross Sector Conf	Virtual
September 8	Roadshow	Geneva
September 9	Roadshow	Zurich
September 15	UBS Best of Switzerland Conference	Virtual
September 16	J.P. Morgan CEO Call Series	Virtual
September 17	Bank of America Global Healthcare Conference	Virtual
September 22	Bernstein Strategic Decision Conference	Virtual
October 28	Third-quarter results	Webcast


32

straumanngroup


32

Straumann Group's currency exposure


Revenue breakdown H1 2021



Total cost breakdown H1 2021



Exchange rates development Jan 2020 - Jun 2021



Average exchange rates (rounded)					FX sensitivity (+/- 10%) on FY
		2019	2020	HY1 2021	Revenue
1	EURCHF	1.11	1.07	1.09	+/- 31m
1	USDCHF	0.99	0.94	0.91	+/- 27m
1	BRLCHF	0.251	0.185	0.170	+/- 4m
1	CNYCHF	0.144	0.136	0.140	+/- 11m

straumanngroup

33

33



Thank you

straumanngroup

34